Industry News Archives - PANTHERx Rare

The Top 15 Specialty Pharmacies of 2025 (PANTHERx #6)

PANTHERx Rare — Tue, 21 Apr 2026 13:03:00 +0000

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs.

For 2025, DCI has identified more than 1,900 dispensing locations with specialty pharmacy accreditation from one or both of the two major independent accreditation organizations. The overall number of accredited locations grew by only 3% in 2025, but is more than five times larger than the 2015 figure.

The post The Top 15 Specialty Pharmacies of 2025 (PANTHERx #6) appeared first on PANTHERx Rare.

The Rare Journey Needs a Special Pharmacy Partner

PANTHERx Rare — Fri, 27 Mar 2026 13:27:10 +0000

PANTHERx Rare’s CEO, Bansi Nagji, authored an insightful guest post for Drug Channels Institute titled, “The Rare Journey Needs a Special Pharmacy Partner.” He makes the case that rare pharmacy is not simply a subset of specialty pharmacy—it requires an entirely different ecosystem. In the post, Bansi also details several key differences between rare pharmacy and traditional specialty, and why these differences enable the depth required to deliver hyper-personalized care to those living with rare conditions.

Download PDF | Read post at Drug Channels >

The post The Rare Journey Needs a Special Pharmacy Partner appeared first on PANTHERx Rare.

The Top 15 U.S. Pharmacies of 2025 (PANTHERx® Rare #11)

PANTHERx Rare — Tue, 17 Mar 2026 21:07:15 +0000

Next week, the Drug Channels Institute (DCI) will release our 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This 17th edition provides our most comprehensive and up-to-date examination of the U.S. drug pricing, reimbursement, and dispensing system.

For 2025, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty pharmacies reached $751 billion in 2025, up 10% from the 2024 figure.

Fierce Healthcare: Survey: Many rare disease patients struggle to navigate care

PANTHERx Rare — Thu, 26 Feb 2026 17:15:19 +0000

Communication gaps, preventable delays and limited support place significant responsibility on patients on the rare disease journey, a new survey finds.

The survey (PDF) was conducted by PANTHERx Rare, an independent specialty pharmacy focused on rare diseases, alongside Morning Consult. It was fielded this month and reached 226 patients, providers and payers. The results, released ahead of Rare Disease Day on February 28, capture the real-world experiences of stakeholders in the rare disease community.

“Rare disease is no longer a niche area,” Richard Faris, Ph.D., chief commercial and clinical officer at PANTHERx Rare, told Fierce Healthcare in an emailed comment. “It’s becoming central to how the industry grows.”

The post Fierce Healthcare: Survey: Many rare disease patients struggle to navigate care appeared first on PANTHERx Rare.

Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different

PANTHERx Rare — Fri, 09 Jan 2026 13:23:29 +0000

In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard Faris, details why precision, partnership, and patient focus are critical to successful rare disease market entries. He also explores how “launch levers” such as early ecosystem collaboration, aligned data and technology, and a strong payer value story can help manufacturers and their pharmacy partners deliver innovative rare treatments to eligible patients quickly after FDA approval.

Download PDF | Read post at Drug Channels >

The post Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different appeared first on PANTHERx Rare.

PANTHERx Rare Submits Comment Letter for FDA’s Rare Disease Innovation, Science and Exploration (RISE) Workshop Series

PANTHERx Rare — Mon, 05 Jan 2026 13:00:00 +0000

Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public comment on its Rare Disease Innovation, Science, and Exploration (RISE) workshop series. The proposal highlights the critical role of real-world evidence (RWE) and patient-reported outcomes (PROs) in strengthening the evidence base for FDA review and approval of rare disease therapies, especially when traditional clinical trial frameworks face limitations due to small numbers of patients and other factors.

By leveraging the unique role of specialty pharmacies focused on people living with rare conditions, we can help capture and analyze meaningful data to inform regulatory science, improve patient outcomes, and accelerate access to life-changing treatments.

Dr. Richard Faris, Chief Commercial & Clinical Officer at PANTHERx Rare, elected to the Board of Directors for the National Association of Specialty Pharmacy (NASP)

PANTHERx Rare — Tue, 16 Sep 2025 17:00:00 +0000

Dr. Richard Faris, PhD, MSc, RPh, will bring his extensive expertise to NASP, helping to guide the organization as it advances specialty pharmacy, promotes innovation, and strengthens patient care and support services. His leadership at PANTHERx, where he drives initiatives to deliver personalized support and improve outcomes for patients with rare and complex conditions, aligns closely with NASP’s mission to ensure all patients have access to life-saving medications and the high-touch care they need.

New article from PANTHERx CEO, Bansi Nagji, explores how hyper-personalization is reshaping the way we approach rare disease care

PANTHERx Rare — Fri, 12 Sep 2025 15:01:21 +0000

Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights the role of hyper-personalization, empathy, and data in improving outcomes for individuals with rare and orphan conditions, while also pointing to lessons that may extend across the broader healthcare landscape.

Download PDF | Read post at Drug Channels >

The post New article from PANTHERx CEO, Bansi Nagji, explores how hyper-personalization is reshaping the way we approach rare disease care appeared first on PANTHERx Rare.

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

PANTHERx Rare — Fri, 07 Feb 2025 15:00:00 +0000

Dr. Richard Faris outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services HUBs.

Download PDF | Read post at Drug Channels >

The post Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner appeared first on PANTHERx Rare.

Q1 2022: PANTHERx Earns #1 Ranking in Quarterly MMIT Patient Satisfaction Survey

PANTHERx Rare — Fri, 03 Jun 2022 19:23:31 +0000

PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by MMIT, an independent national survey entity. For the first quarter of 2022, PANTHERx obtained the highest Net Promoter Score (NPS) among all independent specialty pharmacies surveyed. Net Promoter Score (NPS) is compiled by asking patients, on a scale of 0 to 10, how likely they would be to recommend their specialty pharmacy to a friend or family member. With an NPS of 94 (out of 100), PANTHERx scored 50% higher than the industry average.

“At PANTHERx, we pride ourselves on providing superior services and white-glove care to all of the people we serve. The MMIT Patient Satisfaction survey allows us to quantitatively confirm quarter after quarter that our patients are feeling the work that our associates put forth and are satisfied with our efforts to deliver the best possible experiences,” said Rob Snyder, President of PANTHERx Rare. “I would like to thank and congratulate our associates for their extraordinary daily contributions to our company, the people and families we support, and the rare disease community.”

The PANTHERx team is honored to be held in such high regard by our patients. The critical feedback afforded by the MMIT Patient Satisfaction survey allows PANTHERx to measure success and adjust our programs to the needs and desires of the patients we serve. Data from the 2022 Q1 results illustrate:

100% of patients surveyed indicated that they are satisfied with medication fill and refill times
100% of patients surveyed indicated that they are satisfied with the amount of time it takes to speak with a live person, putting PANTHERx in the lead in this category when compared to the other 10 participating independent specialty pharmacies
when patients were asked how they would feel if forced to change specialty pharmacies, 93% responded that they would be very unhappy
Surveyed patients note PANTHERx key differentiators as: refill reminders, amazing service, and professional and knowledgeable

About PANTHERx Rare

PANTHERx Rare is one of the largest and fastest growing rare pharmacies in the United States. PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions. Although the overall incidence of rare diseases is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an FDA-approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.

PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a five-time winner of the prestigious MMIT Patient Choice Award, including the 2022 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.

The post Q1 2022: PANTHERx Earns #1 Ranking in Quarterly MMIT Patient Satisfaction Survey appeared first on PANTHERx Rare.